Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms

Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19.

MHRA approves GSK’s RSV vaccine for older adults in the UK – Pharmaceutical Technology

Each year in the UK, RSV is estimated to cause 14,000 hospitalisations and 8,000 deaths in adults ages 60 and over. Image credit: Shutterstock/Phawat Older

July 10, 2023

New animation series launched to improve parental understanding of brain development in premature infants

Professor Caroline Hartley, Principal Investigator, and Dr Marianne van der Vaart, Postdoctoral Researcher, in the Paediatric Neuroimaging Group at the Department of Paediatrics, have today

March 7, 2024

Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried

LONDON — A major shakeup in how the benefits of medicines are assessed in Europe is looming, and developers of treatments like gene therapies are

June 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.